Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 7/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.51 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.45 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.45 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479107 | 0.95 | LPAR1 (0.51) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL9479138 | 0.95 | LPAR1 (0.51) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL570522 | 0.95 | LPAR1 (0.51) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL8373393 | 0.95 | LPAR1 (0.51) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL9479464 | 0.95 | LPAR1 (0.51) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL12341018 | 0.95 | LPAR1 (0.51) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL9162390 | 0.92 | USP2 (0.53) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL9478114 | 0.89 | LPAR1 (0.46) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL9478355 | 0.89 | LPAR1 (0.46) | LPAR1LPAR3CES2LPAR2PLA2G2C | |
| SCHEMBL9480222 | 0.89 | LPAR1 (0.46) | LPAR1LPAR3CES2LPAR2PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806350-A2 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO International B.V. (NL) | 2007-07-11 | — | — | EP | disclosed |
| US-6652834-B2 | Tensioactive properties, long lasting activity in the blood pool | BRACCO INTERNATIONAL B.V. (NL) | 2003-11-25 | — | — | US | disclosed |
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO INTERNATIONAL B.V. | 2002-07-25 | — | — | US | disclosed |
| US-6342598-B1 | BLOOD-POOL CONTRAST AGENTS OF OUTSTANDING LONG LIFE IN CIRCULATION | BRACCO INTERNATIONAL B.V. (NL) | 2002-01-29 | — | — | US | disclosed |
| EP-1153029-A2 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000030688-A2 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | SLC39A14, HAMP, PICALM | LPAR1 1795/4885LPAR3 970/4885CES2 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.